Compare Mesoblast Limited (MESO) vs ThredUp Inc (TDUP) Price & Performance

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

TDUP trades at $6.57, down 0.45% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth of 15% year-over-year to $81.7 million, though it missed EPS expectations. Analyst consensus is bullish with a $6.90 price target, and recent news highlights AI integration and a new peer-to-peer marketplace launch.

The outlook is cautiously optimistic due to strong revenue growth and improving gross margins, but persistent net losses and negative ROE pose risks. Upside potential exists if profitability improves, yet investors face execution and competitive threats in the resale market.